Hemostatic Alterations in Patients with Obstructive Sleep Apnea and the Implications for Cardiovascular Disease

Chest

Volumn 124, Issue 5, 2003, Pages 1956-1967

  Von Känel, Roland ^b   Dimsdale, Joel E ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b ETH ZURICH   (Switzerland)

Author keywords

Blood coagulation; Cardiovascular disease; Catecholamines; Cerebrovascular disease; Fibrinolysis; Hemostasis; Hypoxia; Obstructive sleep apnea; Sympathetic nervous system

Indexed keywords

ADRENALIN; BLOOD CLOTTING FACTOR 7; FIBRINOGEN; PROCOAGULANT;

ADRENALIN BLOOD LEVEL; ADRENERGIC SYSTEM; ADULT; APNEA; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HEMOSTASIS; HUMAN; HYPOXEMIA; MAJOR CLINICAL STUDY; MALE; MOLECULAR MECHANICS; OXYGEN SATURATION; PHYSIOLOGY; POSITIVE END EXPIRATORY PRESSURE; PREDICTION; PRIORITY JOURNAL; REVIEW; SLEEP APNEA SYNDROME; VASCULAR DISEASE;

EID: 10744229839     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.124.5.1956     Document Type: Article

References (106)

1. Hung J, Whitford EG, Parsons RW, et al. Association of sleep apnoea with myocardial infarction in men. Lancet 1990; 336:261-264
2. Peker Y, Hedner J, Kraiczi H, et al. Respiratory disturbance index: an independent predictor of mortality in coronary artery disease. Am J Respir Crit Care Med 2000; 162:81-86
3. Dyken ME, Somers VK, Yamada T, et al. Investigating the relationship between stroke and obstructive sleep apnea. Stroke 1996; 27:401-407
4. Bassetti C, Aldrich MS. Sleep apnea in acute cerebrovascular diseases: final report on 128 patients. Sleep 1999; 22:217-223
5. Partinen M, Jamieson A, Guilleminault C. Long-term outcome for obstructive sleep apnea syndrome patients: mortality. Chest 1988; 94:1200-1204
6. Dean RT, Wilcox I. Possible atherogenic effects of hypoxia during obstructive sleep apnea. Sleep 1993; 16:S15-S22
7. Lanfranchi P, Somers VK. Obstructive sleep apnea and vascular disease. Respir Res 2001; 2:315-319
8. Peppard PE, Young T, Palta M, et al. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 2000; 342:1378-1384
9. Grunstein RR, Stenlof K, Hedner J, et al. Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) Study. Int J Obes Relat Metab Disord 1995; 19:410-418
10. Kashyap R, Hock LM, Bowman TJ. Higher prevalence of smoking in patients diagnosed as having obstructive sleep apnea. Sleep Breath 2001; 5:167-172
11. Shepard JW Jr. Hypertension, cardiac arrhythmias, myocardial infarction, and stroke in relation to obstructive sleep apnea. Clin Chest Med 1992; 13:437-458
12. Coy TV, Dimsdale JE, Ancoli-Israel S, et al. Sleep apnoea and sympathetic nervous system activity: a review. J Sleep Res 1996; 5:42-50
13. Chin K, Nakamura T, Shimizu K, et al. Effects of nasal continuous positive airway pressure on soluble cell adhesion molecules in patients with obstructive sleep apnea syndrome. Am J Med 2000; 109:562-567
14. Ohga E, Nagase T, Tomita T, et al. Increased levels of circulating ICAM-1, VCAM-1, and L-selectin in obstructive sleep apnea syndrome. J Appl Physiol 1999; 87:10-14
15. Kato M, Roberts-Thomson P, Phillips BG, et al. Impairment of endothelium-dependent vasodilation of resistance vessels in patients with obstructive sleep apnea. Circulation 2000; 102:2607-2610
16. El-Solh AA, Mador MJ, Sikka P, et al. Adhesion molecules in patients with coronary artery disease and moderate-to-severe obstructive sleep apnea. Chest 2002; 121:1541-1547
17. Phillips BG, Narkiewicz K, Pesek CA, et al. Effects of obstructive sleep apnea on endothelin-1 and blood pressure. J Hypertens 1999; 17:61-66
18. Ip MS, Lam B, Chan LY, et al. Circulating nitric oxide is suppressed in obstructive sleep apnea and is reversed by nasal continuous positive airway pressure. Am J Respir Crit Care Med 2000; 162:2166-2171
19. Hansson GK. Immune mechanisms in atherosclerosis. Arterioscler Thromb Vase Biol 2001; 21:1876-1890
20. Vallet B, Wiel E. Endothelial cell dysfunction and coagulation. Crit Care Med 2001; 29(7 Suppl):S36-S41
21. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126
22. Edwards RL, Rickles FR. The role of leukocytes in the activation of blood coagulation. Semin Hematol 1992; 29: 202-212
23. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 2001; 86:746-756
24. Lowe GD, Yarnell JW, Rumley A, et al. C-reactive protein, fibrin d-dimer, and incident ischemic heart disease in the Speedwell study: are inflammation and fibrin turnover linked in pathogenesis? Arterioscler Thromb Vasc Biol 2001; 21: 603-610
25. Freedman JE, Loscalzo J. Platelet-monocyte aggregates: bridging thrombosis and inflammation. Circulation 2002; 105:2130-2132
26. Clarenbach P, Wessendorf T. Sleep and stroke. Rev Neurol 2001; 157:S46-S52
27. Koenig W. Haemostatic risk factors for cardiovascular diseases. Eur Heart J 1998; 19(Suppl C);C39-C43
28. Folsom AR. Hemostatic risk factors for atherothrombotic disease: an epidemiologic view. Thromb Haemost 2001; 86:366-373
29. von Känel R, Mills PJ, Fainman C, et al. Effects of psychological stress and psychiatric disorders on blood coagulation and fibrinolysis: a biobehavioral pathway to coronary artery disease? Psychosom Med 2001; 63:531-544
30. Catto AJ, Grant PJ. Risk factors for cerebrovascular disease and the role of coagulation and fibrinolysis. Blood Coagul Fibrinolysis 1995; 6:497-510
31. Maresca G, Di Blasio A, Marchioli R, et al. Measuring plasma fibrinogen to predict stroke and myocardial infarction: an update. Arterioscler Thromb Vasc Biol 1999; 19:1368-1377
32. Danesh J, Whincup P, Walker M, et al. Fibrin d-dimer and coronary heart disease: prospective study and meta analysis. Circulation 2001; 103:2323-2327
33. Davies MJ. The contribution of thrombosis to the clinical expression of coronary atherosclerosis. Thromb Res 1996; 82:1-32
34. Virmani R, Kolodgie FD, Burke AP, et al. Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000; 20:1262-1275
35. Swords Jenny N, Mann KG. Coagulation cascade: an overview. In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage. 2nd ed. Baltimore, MD: Williams & Wilkins, 1998; 3-8
36. Roberts HR, Monroe DM, Oliver JA, et al. Newer concepts of blood coagulation. Haemophilia 1998; 4:331-334
37. Kroll HK, Sullivan R. Mechanisms of platelet activation. In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage. 2nd ed. Baltimore, MD: Williams & Wilkins, 1998; 261-262,282
38. Peerschke EIB, López JA. Platelet membranes and receptors. In: Loscalzo J, Schafer AI, eds. Thrombosis and hemorrhage. 2nd ed. Baltimore, MD: Williams & Wilkins, 1998; 252
39. Meyer D, Girma JP. von Willebrand factor: structure and function. Thromb Haemost 1993; 70:99-104
40. Harker LA, Mann KG. Thrombosis and fibrinolysis. In: Verstraete M, Fuster V, Topol EJ, eds. Cardiovascular thrombosis: thrombocardiology and thromboneurology. 2nd ed. Philadelphia, PA: Lippincott-Raven, 1998; 17-18
41. Collen D, Wiman B. Turnover of antiplasmin, the fast-acting plasmin inhibitor of plasma. Blood 1979; 53:313-324
42. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in humans: insights gained from studies using markers of hemostatic system activation. Blood 1987; 70:343-350
43. Amiral J, Fareed J. Thromboembolic diseases: biochemical mechanisms and new possibilities of biological diagnosis. Semin Thromb Hemost 1996; 22(suppl 1):41-48
44. Rangemark C, Hedner JA, Carlson JT, et al. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients. Sleep 1995; 18:188-194
45. Bokinsky G, Miller M, Ault K, et al. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure: a preliminary investigation. Chest 1995; 108:625-630
46. Chin K, Ohi M, Kita H, et al. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 1996; 153:1972-1976
47. Eisensehr I, Ehrenberg BL, Noachtar S, et al. Platelet activation, epinephrine, and blood pressure in obstructive sleep apnea syndrome. Neurology 1998; 51:188-195
48. Chin K, Kita H, Noguchi T, et al. Improvement of factor VII clotting activity following long-term NCPAP treatment in obstructive sleep apnoea syndrome. QJM 1998; 91:627-633
49. Sanner BM, Konermann M, Tepel M, et al. Platelet function in patients with obstructive sleep apnoea syndrome. Eur Respir J 2000; 16:648-652
50. Wessendorf TE, Thilmann AF, Wang YM, et al. Fibrinogen levels and obstructive sleep apnea in ischemic stroke. Am J Respir Crit Care Med 2000; 162:2039-2042
51. Nobili L, Schiavi G, Bozano E, et al. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome. Clin Hemorheol Microcirc 2000; 22:21-27
52. von Känel R, Le DT, Nelesen RA, et al. The hypercoagulable state in sleep apnea is related to comorbid hypertension. J Hypertens 2001; 19:1445-1451
53. Geiser T, Buck F, Meyer BJ, et al. In vivo platelet activation is increased during sleep in patients with obstructive sleep apnea syndrome. Respiration 2002; 69:229-234
54. Rechtschaffen A, Kales A, eds. A manual of standardized terminology, techniques and scoring system for sleep stages of human subjects. Washington, DC: National Institutes of Health, 1968; Publication No. 204
55. Bartsch P, Straub PW, Haeberli A. Hypobaric hypoxia. Lancet 2001; 357:955-956
56. Schneider DJ, Tracy PB, Mann KG, et al. Differential effects of anticoagulants on the activation of platelets ex vivo. Circulation 1997; 96:2877-2883
57. Geffken DF, Keating FG, Kennedy MH, et al. The measurement of fibrinogen in population-based research: studies on instrumentation and methodology. Arch Pathol Lab Med 1994; 118:1106-1109
58. Phillips B, Collop N, Strollo P. Controversies in sleep disorders medicine: pulmonologists respond! Chest 1996; 110: 1597-1602
59. Barcelo A, Llompart E, Barbe F, et al. Plasminogen activator inhibitor-I (PAI-I) polymorphisms in patients with obstructive sleep apnoea. Respir Med 2002; 96:193-196
60. Labrecque G, Soulban G. Biological rhythms in the physiology and pharmacology of blood coagulation. Chronobiol Int 1991; 8:361-372
61. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991; 8:336-351
62. Frohlich M, Sund M, RUSS S, et al. Seasonal variations of rheological and hemostatic parameters and acute-phase reactants in young, healthy subjects. Arterioscler Thromb Vasc Biol 1997; 17:2692-2697
63. Young T, Peppard PE, Gottlieb DJ. Epidemiology of obstructive sleep apnea: a population health perspective. Am J Respir Crit Care Med 2002; 165:1217-1239
64. Lip GY. Hypertension and the prothrombotic state. J Hum Hypertens 2000; 14:687-690
65. Beckman JA, Creager MA, Libby P. Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. JAMA 2002; 287:2570-2581
66. Hioki H, Aoki N, Kawano K, et al. Acute effects of cigarette smoking on platelet-dependent thrombin generation. Eur Heart J 2001; 22:56-61
67. Daae LN, Kierulf P, Landaas S, et al. Cardiovascular risk factors: interactive effects of lipids, coagulation and fibrinolysis. Scand J Clin Lab Invest Suppl 1993; 215:19-27
68. Winkler UH. Obesity and haemostasis. Arch Gynecol Obstet 1997; 261:25-29
69. Fletcher EC. The relationship between systemic hypertension and obstructive sleep apnea: facts and theory. Am J Med 1995; 98:118-128
70. Yudkin JS. Abnormalities of coagulation and fibrinolysis in insulin resistance: evidence for a common antecedent? Diabetes Care 1999; 22(Suppl 3):C25-C30
71. Ip MS, Lam B, Ng MM, et al. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med 2002; 165:670-676
72. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32(Suppl 1):78-84
73. Veenstra J, Kluft C, Ockhuizen TH, et al. Effects of moderate alcohol consumption on platelet function, tissue-type plasminogen activator and plasminogen activator inhibitor. Thromb Haemost 1990; 63:345-348
74. Hendriks HF, Veenstra J, Velthuis-te Wierik EJ, et al. Effect of moderate dose of alcohol with evening meal on fibrinolytic factors. BMJ 1994; 308:1003-1006
75. Bak AA, Grobbee DE. Coffee, caffeine and hemostasis: a review. Neth J Med 1990; 37:242-246
76. el-Sayed MS. Effects of exercise on blood coagulation, fibrinolysis and platelet aggregation. Sports Med 1996; 22:282-298
77. Colella A, Abbate R, Gensini GF. Evaluation of clotting and fibrinolytic activation after protracted physical exercise. Thromb Res 1998; 89:73-78
78. Jorgensen KA, Sorensen P, Freund L. Effect of glucocorticosteroids on some coagulation tests. Acta Haematol 1982; 68:39-42
79. Schussheim AE, Fuster V. Thrombosis, antithrombotic agents, and the antithrombotic approach in cardiac disease. Prog Cardiovasc Dis 1997; 40:205-238
80. Jimenez AH, Stubbs ME, Tofler GH, et al. Rapidity and duration of platelet suppression by enteric-coated aspirin in healthy young men. Am J Cardiol 1992; 69:258-262
81. Felmeden DC, Lip GY. The renin-angiotensin-aldosterone system and fibrinolysis. J Renin Angiotensin Aldosterone Syst 2000; 1:240-244
82. Hjemdahl P, Wallen NH. Calcium antagonist treatment, sympathetic activity and platelet function. Eur Heart J 1997; 18(Suppl A):A36-A50
83. Winther K, Gleerup G, Hedner T. Platelet function and fibrinolytic activity in hypertension: differential effects of calcium antagonists and beta-adrenergic receptor blockers. J Cardiovasc Pharmacol 1991; 18(Suppl 9):S41-S44
84. von Känel R, Dimsdale JE. Effects of sympathetic activation by adrenergic infusions on hemostasis in vivo. Eur J Haematol 2000; 65:357-369
85. Wallen NH, Goodall AH, Li N, et al. Activation of haemostasis by exercise, mental stress and adrenaline: effects on platelet sensitivity to thrombin and thrombin generation. Clin Sci 1999; 97:27-35
86. Herren T, Bartsch P, Haeberli A, et al. Increased thrombinantithrombin III complexes after 1 h of physical exercise. J Appl Physiol 1992; 73:2499-2504
87. von Känel R, Dimsdale JE, Ziegler MG, et al. Effect of acute psychological stress on the hypercoagulable state in subjects (spousal caregivers of patients with Alzheimer's disease) with coronary or cerebrovascular disease and/or systemic hypertension. Am J Cardiol 2001; 87:1405-1408
88. 2,-adrenergic receptor functioning and increased norepinephrine on the hypercoagulable state with mental stress. Am Heart J 2002; 144:68-72
89. 2-adrenergic vascular response in patients with obstructive sleep apnea. Am J Respir Crit Care Med 2000; 162:1480-1487
90. 2-Adrenergic receptor characteristics in sleep apnea patients. Sleep 1995; 18:39-42
91. Le Roux G, Larmignat P, Marchal M, et al. Haemostasis at high altitude. Int J Sports Med 1992; 13(Suppl 1):S49-S51
92. Imoberdorf R, Garlick PJ, McNurlan MA, et al. Enhanced synthesis of albumin and fibrinogen at high altitude. J Appl Physiol 2001; 90:528-537
93. Bartsch P, Haeberli A, Hauser K, et al. Fibrinogenolysis in the absence of fibrin formation in severe hypobaric hypoxia. Aviat Space Environ Med 1988; 59:428-432
94. Bendz B, Rostrup M, Sevre K, et al. Association between acute hypobaric hypoxia and activation of coagulation in human beings. Lancet 2000; 356:1657-1658
95. Bendz B, Sevre K, Andersen TO, et al. Low molecular weight heparin prevents activation of coagulation in a hypobaric environment. Blood Coagul Fibrinolysis 2001; 12:371-374
96. Wedzicha JA, Syndercombe-Court D, Tan KC. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxaemia. Thorax 1991; 46:504-507
97. Kisker CT, Robillard JE, Clarke WR. Blood coagulation changes after hypoxemia: a fetal lamb model. Pediatr Res 1982; 16:8-12
98. Nakanishi K, Tajima F, Nakata Y, et al. Hypercoagulable state in a hypobaric, hypoxic environment causes non-bacterial thrombotic endocarditis in rats. J Pathol 1997; 181:338-346
99. Lawson CA, Yan SD, Yan SF, et al. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 1997; 99:1729-1738
100. Yan SF, Mackman N, Kisiel W, et al. Hypoxia/hypoxemia-induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 1999; 19:2029-2035
101. Pinsky DJ, Liao H, Lawson CA, et al. Coordinated induction of plasminogen activator inhibitor-1 (PAI-1) and inhibition of plasminogen activator gene expression by hyporia promotes pulmonary vascular fibrin deposition. J Clin Invest 1998; 102:919-928
102. Gertler JP, Weibe DA, Ocasio VH, et al. Hypoxia induces procoagulant activity in cultured human venous endothelium. J Vasc Surg 1991; 13:428-433
103. Lip GYH, Edmunds E, Beevers DG. Should patients with hypertension receive antithrombotic therapy? J Intern Med 2001; 249:205-214
104. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002; 136:161-172
105. Patrono C. Prevention of myocardial infarction and stroke by aspirin: Different mechanisms? Different dosage? Thromb Res 1998; 92(1 Suppl):S7-S12
106. Hla KM, Young TB, Bidwell T, et al. Sleep apnea and hypertension: a population-based study. Ann Intern Med 1994; 120:382-388